Compare Carvana Co (CVNA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs BIO-TECHNE Corp — how do they compare? Carvana Co trades at $64.08 (market cap $69.55B), while BIO-TECHNE Corp trades at $72.47 (market cap $11.36B). The key difference: Carvana Co is far larger — about 6.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and BIO-TECHNE Corp for 63 Days on average.
| CVNA | TECH | |
|---|---|---|
Market Cap | $69.55B | $11.36B |
Volume | 7,671,750 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $72.61 |
52-Week Low | $56.27 | $43.31 |
Typical Hold Time | 28 Days | 63 Days |
Enterprise Value | $72.04B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% with bearish technical signals but strong fundamental momentum. The stock shows impressive revenue growth from $13.7B in 2024 to $20.3B in 2025, with net income surging to $1.4B. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding the $0.39 forecast. Analyst sentiment remains divided with a $84.07 consensus target, though technical indicators show selling pressure with bearish moving averages and key resistance at $64.
Carvana presents a compelling growth story with expanding profitability and operational efficiency, though high valuation multiples and significant debt levels warrant caution. The company's aggressive capacity expansion addresses demand constraints, positioning it for continued market share gains in online auto retail. However, competitive pressures and macroeconomic sensitivity to interest rates remain key risks for investors.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
